Hematology/oncology requires clinicians to have some of the most difficult conversations in all of medicine. In this edition, we begin a three-part series about having those conversations. 

These conversations will be hosted by Ilana Yurkiewicz, MD, the host and producer of the Clinical Correlation segment and the author of Hard Questions, a monthly column at MDedge Hematology-Oncology. She is joined by the two residents who have been behind Blood & Cancer show notes from the beginning, Emily Bryer, DO, and Ronak Mistry, DO, both of the University of Pennsylvania, Philadelphia.

David H. Henry, MD, editor in chief of MDedge Hematology-Oncology and the host of Blood & Cancer, joins the podcast to talk about this week's discussion and a new Food and Drug Administration approval from earlier in September.  

Time stamps:

• Intro (00:05)
• This Week in Oncology (04:11)
• Conversation (07:30)

Links:

• This Week in Oncology: 
  • FDA approves pembrolizumab/lenvatinib combo for advanced endometrial carcinoma
• Ilana Yurkiewicz, MD:
  • Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford (Calif.) University.
  • Hard Questions
• Emily Bryer, DO
• Ronak Mistry, DO

 

For more MDedge podcasts, go to mdedge.com/podcasts

Email the show: [email protected]

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Ilana Yurkiewicz on Twitter: @ilanayurkiewicz